FBX23 Activators
FBX23 activators, through their influence on protein synthesis and degradation pathways, indirectly enhance the functional activity of FBX23. Compounds such as Cycloheximide and Tunicamycin disrupt protein folding and glycosylation, respectively. This disruption leads to an increased pool of misfolded proteins, which could enhance the demand for FBX23-mediated ubiquitination as the cell seeks to maintain proteostasis. Similarly, proteasome inhibitors like MG132, Epoxomicin, Bortezomib, and Lactacystin increase the level of ubiquitinated proteins within the cell by preventing their degradation. This accumulation can signal a need to upregulate the ubiquitination process, enhancing the activity of ubiquitin ligases such as FBX23. In the case of MLN4924, by inhibiting NEDD8-activating enzyme, the drug can cause an increase in the substrates available for ubiquitination, which might indirectly stimulate the activity of F-box proteins including FBX23. PYR-41, although an inhibitor of ubiquitination, could also result in a feedback mechanism that enhances FBX23's role in a stressed cellular environment.
Thalidomide and its derivatives exert their effects by targeting certain proteins for degradation; the altered levels of these proteins can indirectly affect the ubiquitination cycle, heightening the role of FBX23 in this process. Furthermore, oxidative stress inducers like the oxidized form of glutathione and sodium arsenite can lead to protein misfolding, which may subsequently increase the requirement for FBX23-mediated ubiquitination.
SEE ALSO...
Items 1 to 10 of 11 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $40.00 $82.00 $256.00 | 127 | |
Cycloheximide inhibits eukaryotic protein synthesis by interfering with translational elongation. This leads to an accumulation of misfolded proteins, which may increase the demand for proteasomal degradation and indirectly enhance the functional activity of FBX23 in targeting proteins for ubiquitination. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $56.00 $260.00 $980.00 | 163 | |
MG132 is a proteasome inhibitor that prevents the degradation of ubiquitinated proteins. By inhibiting the proteasome, MG132 can indirectly increase the pool of ubiquitinated substrates, potentially enhancing the activity of FBX23 as it targets additional proteins for ubiquitination. | ||||||
Epoxomicin | 134381-21-8 | sc-201298C sc-201298 sc-201298A sc-201298B | 50 µg 100 µg 250 µg 500 µg | $134.00 $215.00 $440.00 $496.00 | 19 | |
Epoxomicin is a selective proteasome inhibitor. Similar to MG132, it increases the level of ubiquitinated proteins, potentially enhancing the functional activity of FBX23 by increasing its substrate pool. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $132.00 $1064.00 | 115 | |
Bortezomib is another proteasome inhibitor that could indirectly enhance the activity of FBX23 by increasing the pool of ubiquitinated proteins needing degradation, thereby potentially upregulating the activity of the SCF complex in which FBX23 operates. | ||||||
MLN 4924 | 905579-51-3 | sc-484814 | 1 mg | $280.00 | 1 | |
MLN4924 inhibits NEDD8-activating enzyme, which is essential for the neddylation that activates Cullin-RING ligases (CRLs). By inhibiting this activation step, MLN4924 can lead to the accumulation of substrates that would be targeted by FBX23, indirectly enhancing its activity. | ||||||
Ubiquitin E1 Inhibitor, PYR-41 | 418805-02-4 | sc-358737 | 25 mg | $360.00 | 4 | |
PYR-41 is an inhibitor of the ubiquitin-activating enzyme E1. While it primarily inhibits ubiquitination, in certain contexts, it may lead to the accumulation of proteins that could be substrates for FBX23, potentially enhancing its activity in a feedback mechanism. | ||||||
Thalidomide | 50-35-1 | sc-201445 sc-201445A | 100 mg 500 mg | $109.00 $350.00 | 8 | |
Thalidomide and its analogs (immunomodulatory imide drugs) can lead to the degradation of specific transcription factors. This can result in altered protein expression profiles that may indirectly enhance the activity of FBX23 by increasing the levels of proteins that are its substrates. | ||||||
Lactacystin | 133343-34-7 | sc-3575 sc-3575A | 200 µg 1 mg | $165.00 $575.00 | 60 | |
Lactacystin is a specific inhibitor of the proteasome. By blocking proteasomal degradation, it may indirectly enhance FBX23 activity through the accumulation of ubiquitinated proteins. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $169.00 $299.00 | 66 | |
Tunicamycin blocks N-linked glycosylation, leading to the buildup of misfolded glycoproteins in the endoplasmic reticulum. This can enhance the activity of FBX23 by increasing the need for degradation of these misfolded proteins. | ||||||
Glutathione, oxidized | 27025-41-8 | sc-29093B sc-29093A sc-29093 | 250 mg 1 g 5 g | $57.00 $82.00 $270.00 | 3 | |
The oxidized form of glutathione can create an oxidative environment that may lead to protein misfolding, indirectly enhancing the activity of FBX23 by increasing the pool of proteins requiring ubiquitination and subsequent degradation. | ||||||